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A B S T R A C T
Purpose: The aim of our study was to detect objective signs of deterioration of motor performance in
epilepsy patients treated with chronic valproate therapy.
Methods: We examined 14 controls and 15 epilepsy patients receiving chronic valproate monotherapy,
who had no subjective complaints related to motor function. Regularity and maximum frequency of
repetitive hand and ﬁnger movements, and simple reaction time were measured. Intensity and
frequency characteristics of resting and postural tremor were assessed using accelerometry. Data were
statistically evaluated.
Results: Repetitive hand and ﬁnger movements were signiﬁcantly more irregular and the maximum
frequency of repetitive movements was signiﬁcantly lower in the valproate group than in controls.
Resting tremor peak frequency and motor reaction time of the two cohorts did not differ.
Conclusions: This is the ﬁrst study, which quantitatively assesses motor performance of patients with
epilepsy on chronic valproate therapy. The results suggest signiﬁcant irregularity of repetitive hand
movements and ﬁnger tapping even in patients with no motor complaints. Objective methods might
help to recognize valproate-induced motor performance deterioration.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Valproate is one of the most frequently prescribed antiepileptic
drugs worldwide.1 The number of patients treated with valproate
is growing since it has been shown to be effective in the
management of bipolar illness,2 and migraine3 as well.
A well-known side effect of valproate is tremor, which might
affect as many as 45% of patients.1 Some studies suggest that
valproate might also induce other motor deﬁcits, like decreased
alternate motion rates, rigidity, abnormalities of posture and gait,
with an incidence of about 5%.4–7 The early motor manifestations
may not be evident unless particularly sought, and the association
with valproate may escape notice due to insidious onset.8
While valproate-induced tremor has already been investigated
using objective methods9–12 the quantitative measurement of
motor performance in patients with chronic valproate medication
has not been performed yet.
Valproate-induced motor symptoms are reversible on with-
drawal of the drug, however the recovery might be slow.6,8 The
reversible nature of the alterations emphasizes the importance of
early recognition, since discontinuation of the drug might be
necessary.* Corresponding author. Tel.: +36 30 370 7673; fax: +36 1 210 1368.
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1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.01.013In the present study, we performed complex quantitative
assessment of motor performance of adults with epilepsy, who
were on chronic valproate monotherapy for at least 2 years, and
had no clinically noticeable motor symptoms. We measured the
regularity and maximum speed of alternating hand and repetitive
ﬁnger movements, the simple motor reaction time and the resting
and postural tremor. Our aim was to detect subclinical changes of
motor performance in valproate-treated patients, which might be
used for early detection of valproate-related motor dysfunction.
2. Subjects and methods
2.1. Subjects
We examined 14 healthy control subjects, who were all
employeesofourDepartment, andhadnohistoryofanyneurological
disorder. Controls did not take any medication regularly.
Fifteen epilepsy patients receiving valproate monotherapy
were selected from the Epilepsy Outpatient Service of our
Department. Inclusion criteria were the following: (1) The patient
has primarily generalized epilepsy with tonic–clonic seizures only,
treated with controlled-release valproate monotherapy for a
minimum of 2 years, and he/she is not taking other medication
regularly. (2) He/she does not have any complaint regarding
tremor or motor abnormality. (3) The patient does not have any
clinically detectable motor symptom (upper motor neuron signs,vier Ltd. All rights reserved.
Table 1
Clinical characteristics of the control and valproate-treated groups.
Parameter Control Valproate
Number of subjects 14 15
Age (year) mean SD 36.313.4 40.715.4
Range 25–65 21–65
Gender (female/male) 7/7 6/9
Epilepsy type – 15 IGE-GTCS
Median daily dosage (mg) – 900 (300–1500)
Serum drug level (mg/l) mean SD – 78.411.76
Range 62–98
Duration of treatment (year) mean SD – 5.24.6
Range 2–13
Median seizure frequency (seizures/year) – 1
Range 0–3
IGE-GTCS: idiopathic generalized epilepsy with tonic–clonic seizures.
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ments) on neurological examination. (4) The number of seizures
per year is less than three. (5) The last seizure occurred at least 2
months before the motor performance assessment. (6) The serum
valproate level does not exceed 100 mg/l measured within 1
month prior motor testing. (7) The patient has a negative CT/MRI
examination performed within 2 years. (8) The Mini Mental State
Examination (MMSE) score is greater than 28. (9) The hematologi-
cal panel, serum TSH, ammonia and vitamin B12 levels are normal.
Clinical characteristics of the groups are shown in Table 1.
There was no signiﬁcant difference between the mean age of the
groups. All subjects were right handed.
Subjects were asked to refrain from taking sleeping pills, and
drinking coffee and/or alcohol 24 h prior to examination, since
these are known to affect tremor, motor coordination and
alertness.13–16 Measurements were carried out within 2 h taking
the regular morning valproate medication.
The study was performed according to the Declaration of
Helsinki. The experimental procedure was approved by the Local
Ethical Committee. All individuals gave written informed consent.
2.2. Recording methods
Tremor parameters and regularity of repetitive movements
were measured using a computerized test system (CATSYS 2000,
Danish Product Development Ltd., Snekkersten, Denmark,
www.catsys.dk).17–19 Patients were seated comfortably in a
soundproof room. Measurements were carried out on the right
and left side consecutively.
Regularity and maximum frequency of repetitive ﬁnger and
alternating hand movements were examined using a touch
sensitive drum.
For ﬁnger tapping measurements, subjects hit the drum with
the index ﬁnger while the wrist was supported.
Alternating hand movements were investigated with the drum
in hand. Subjects were instructed to perform pronation/supination
movements for 10 s, keeping precise pace with the 2.5 Hz acoustic
signal generated by the computer. The time offset (ms) between
the signal and the subject’s beat was measured.
Regularity of repetitive movements was quantiﬁed by the
standard deviation of the time-offset values (tap-to-cue variability,
ms). A subject, who is able to maintain the constant frequency of
2.5 Hz, has a tap-to-cue variability of 30  20 ms for ﬁnger and
40  20 ms for hand pronation/supination movement according to
the normal dataset of CATSYS.19
To deﬁne the maximum frequency (Hz) of repetitive movements
subjects were instructed to perform ﬁnger tapping or hand
pronation/supination paced by gradually accelerating acoustic
signal (from 1.6 to 7.5 Hz). The touch-sensitive period around each
signal, in which the subject’s action was recorded, was 250 ms atstimulus frequency of 1.6 Hz, and it gradually decreased to 50 ms at
stimulus frequency of 7.5 Hz. If the latencyof thehitwas longer than
the touch-sensitive period, the action was not accepted. To
compensate for random errors, subjects were allowed to miss one
hit if the next two were acceptable. The frequency of hand or ﬁnger
movements at the time of the last legal hit determined the
maximum frequency.
Simple motor reaction time (ms) was measured in a traditional
stimulus-response test using a handle switch. The computer gave
random auditory signals to which the subjects had to press the
handle switch with the thumb. Reaction times shorter than 0.1 s or
longer than 0.5 were excluded. Average reaction time of ten trials
was calculated.
Tremor was recorded for 32.8 s in two different positions: (1) at
rest the forearm and the hand was fully supported on the arm-rest
of the chair; (2) in postural position the arm and hand were held
against gravity in an outstretched, horizontal, prone position.
Tremor was measured using a biaxial micro-accelerometer
(weight: 10.5 g, sensitivity: >0.3 m/s2), ﬁxed on the third
metacarpal bone, 2 cm proximal to the metacarpophalangeal
joint. Accelerometry signals of the two axes were digitized at
128 Hz, and combined by root sum of squares. Tremor parameters
were derived from Fourier power spectra. Because of the inter-
individual tremor intensity differences, for frequency power
analysis the power spectrum of each subject was normalized.
Tremor intensity (TI, m/s2) was calculated as the root-mean-
square of acceleration.
Peak frequency (Hz), atwhich the tremorhad thehighestpower in
the spectrum, was determined from the normalized power spectra.
Frequency dispersion (FD, Hz) reﬂects the regularity of tremor. It
is deﬁned as the half width of the frequency band centered around
the peak frequency, which contains 68% of the total power.
Frequency dispersion of the physiological tremor is broad (3–4 Hz),
while it is reduced (0.5–1 Hz) in parkinsonian or essential
tremor.20,21
2.3. Statistical analysis
Our principal experimental hypothesis was that regularity of
alternating hand movements and ﬁnger tapping as well as
physiological tremor were affected in patients treated with VPA.
This hypothesis was examined by non-parametric tests because
data were not normally distributed (Kolmogorov–Smirnov test).
Statistical analysis was performed using the Statistica software
package (Statsoft Inc., 6.0 version, Tulsa, OK, USA).
Regularity data of motor performance of the two groups were
analysed using the Mann–Whitney test.
To assess the tremor power distribution in the 0–15 Hz
spectrum of the two groups, the power of each 1 Hz wide
frequency band (0–0.99, 1–1.99, 2–2.99, etc.) was compared using
the Mann–Whitney test.
To investigate changesof restingandpostural tremorparameters
within one group we used the Wilcoxon-matched-pairs test.
The relationship between duration of medication and various
parameters of hand and ﬁnger movements was examined by
regression analysis.
Level of signiﬁcance for all statistics was set at p < 0.05.
Statistical analysis showed no signiﬁcant difference between the
right and left sides. Data of the right hand are presented.
3. Results
3.1. Motor performance
Individual data of motor performance parameters for controls
and patients are presented in Tables 2a and 2b, respectively. Data
Table 2b
Individual data of motor parameters in the valproate group.
Patients PS Tap MF/PS MF/Tap RT
1 68 32 3.8 7.5 226
2 109 50 4.9 7.5 247
3 33 71 6.7 7.5 208
4 105 73 5.9 6.2 188
5 97 45 6.2 7.5 229
6 23 46 6.7 5.6 225
7 139 101 3.7 4.8 228
8 82 54 4.8 4.6 206
9 108 65 4.7 6.0 286
10 22 54 4.6 6.4 239
11 47 54 5.2 6.4 208
12 96 102 2.6 3.8 317
13 68 87 3.2 5.3 208
14 55 75 4.3 7.5 206
15 71 120 3.0 6.2 258
Av SD 74.8734.6* 68.6024.8* 4.691.3* 6.191.2* 231.9334.0
PS: tap-to-cue variability of pronation–supination (ms); Tap: tap-to-cue variability
of tapping (ms); MF/PS: maximum frequency of pronation/supination (Hz); MF/
Tap: maximum frequency of tapping (Hz); RT: reaction time (ms). Gray shading:
values outside of the mean2SD range of controls.
* p<0.05.
Table 3
Tremor data of the control and the valproate groups.
Parameter Position Control Valproate
Tremor intensity (m/s2) Rest 0.08 0.04 0.09 0.06
Postural 0.17 0.09 0.21 0.08
Peak frequency (Hz) Rest 8.921.38 7.731.98
Postural 7.231.50 6.921.43
Frequency dispersion (Hz) Rest 2.50 0.87 2.77 0.89
Postural 3.33 0.71 3.32 0.80
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population.19
The tap-to-cue variability of the valproate-group was signiﬁ-
cantly greater for both pronation/supination movements and
ﬁnger tapping compared to controls (Tables 2a and 2b).
The individual tap-to-cue variability was longer than the
mean + 2SD of the control group in the pronation/supination test in
11 patients (73%) and in the ﬁnger tapping test in 8 patients (53%).
There was only one value greater than normal in the control group
in the pronation/supination and in the tapping test (Subject No. 13
and 12, respectively) (shaded cells in Tables 2a and 2b). These
ﬁndings show that valproate-treated patients performed alternat-
ing repetitive hand movements and ﬁnger tapping with signiﬁ-
cantly less regularity compared to controls.
There was no signiﬁcant correlation between the duration of
valproate treatment and the severity of either the hand or the
ﬁnger movement irregularity (pronation/supination: r2 = 0.275,
p = 0.267, ﬁnger tapping: r2 = 0.071, p = 0.435). There was also no
correlation between serum level of valproate and motor perfor-
mance deterioration (pronation/supination: r2 = 0.087, p = 0.428,
ﬁnger tapping: r2 = 0.0047, p = 0.562).
The maximum frequency of pronation/supination movements
and ﬁnger tapping was signiﬁcantly lower in valproate patients
compared to controls (Tables 2a and 2b). The individualmaximum
frequency of hand and ﬁnger movements was lower than the
mean  2SD of the control group in 5 valproate-treated patients
(33.3%). There was only one value lower than normal in the control
group in the maximum tapping frequency (Subject No. 11, shaded
values in Tables 2a and 2b).
There was no signiﬁcant correlation between the duration of
valproate treatment and the maximum frequency of either the
hand or the ﬁnger movement (maximum frequency of pronation/
supination: r2 = 0.001, p = 0.506, maximum frequency of ﬁnger
tapping: r2 = 0.053, p = 0.366).
The average reaction time of the two groups was statistically
similar (Tables 2a and 2b).
3.2. Tremor parameters
Data of tremor parameters are presented in Table 3. The results
of the control group were similar to those reported for normal
population.19
Tremor intensity of VPA-patientswas similar to controls both at
rest and in postural position (Table 3). In both groups tremorTable 2a
Individual data of motor parameters in the control group.
Controls PS Tap MF/PS MF/Tap RT
1 19 15 7.1 6.9 259
2 25 16 5.7 7.5 273
3 30 19 5.1 7.3 220
4 19 35 6.1 6.8 283
5 36 36 5.2 7.2 228
6 28 23 5.6 7.5 259
7 27 50 7.5 7.5 224
8 25 32 6.0 6.8 194
9 27 33 6.9 6.9 233
10 21 32 5.4 7.5 206
11 22 33 6.1 5.4 219
12 45 56 4.7 7.5 240
13 50 13 4.4 7.1 236
14 17 40 6.6 7.5 239
Av SD 27.939.7* 30.9312.8* 5.890.9* 7.10.6* 236.6424.9
PS: tap-to-cue variability of pronation–supination (ms); Tap: tap-to-cue variability
of tapping (ms); MF/PS: maximum frequency of pronation/supination (Hz); MF/
Tap: maximum frequency of tapping (Hz); RT: reaction time (ms). Gray shading:
values outside of the mean2SD range of controls.
* p<0.05.intensity was signiﬁcantly higher in postural compared to resting
position, which is in accordance with data of the normal
physiological tremor.18
The peak frequency of rest tremor was lower in the valproate-
group, but the difference did not reach signiﬁcance (Table 3). The
analysis of power distribution showed signiﬁcantly higher power
in the 2–2.99 Hz, 3–3.99 Hz, 5–5.99 Hz and 6–6.99 Hz bands in the
valproate-group compared to controls (Fig. 1). Power values in the
higher frequency bands (from 8 to 15 Hz) were similar in the two
cohorts.Fig. 1. Normalized average tremor power (mean  SE) of the control and valproate-
treated groups. The tremor power was signiﬁcantly higher in the low frequency bands
of the power spectrum in the valproate group compared to controls. There was no
statistically signiﬁcant difference in the higher frequency range (7–15 Hz, data not
shown).
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were similar in the two groups (Table 3). Peak frequency was
signiﬁcantly lower in postural position compared to rest in both
groups, in accordance with normal physiological tremor data.22
Frequency dispersion of rest and postural tremor was similar in
the two groups (Table 3). Postural tremor had signiﬁcantly greater
frequency dispersion value compared to resting tremor in both
groups, similarly towhat can be observed in the normal population.
4. Discussion
We report for the ﬁrst time the results of quantitative analysis
of motor performance in patients with epilepsy treated with
chronic valproate monotherapy. We found that repetitive ﬁnger
and hand movements were signiﬁcantly more irregular and the
maximum frequency of movements was signiﬁcantly lower in
valproate-treated patients than in controls. This deterioration of
motor performance was detected not only at the group level;
individual values of more than 70% of valproate patients fell
outside the normal range (i.e. mean  2SD of the controls).
Irregularity and slowing of repetitive movements were proba-
bly not related to valproate-induced sedation, since the control and
the patient groups performed similarly well in the simple motor
reaction time test. Motor reaction time is a measure of akinesia,23
and our data suggest that valproate-treated patients were not
affected in this respect.
Tremor analysis, in accordance with the inclusion criteria,
showed normal intensity of both rest and postural tremor in both
groups. Chronic valproate administration caused a non-signiﬁcant
decrease of peak frequency of rest tremor, which was due to an
augmentation of tremor power in the lower frequency ranges
(between 2 and 6.99 Hz).
Our data prove that the motor performance of the majority of
valproate-treated patients might already be impaired even when
their tremor still shows physiological characteristics. This suggests
that tremor is probably not the ﬁrst appearingmotor adverse effect
of valproate treatment. Quantitative methods might reveal higher
incidence of valproate related motor disturbances than it is
considered now.
We did not ﬁnd correlation between duration of treatment and
severity of motor deﬁcit or decrease of tremor peak frequency.
There was also no correlation between serum levels of valproate
and degree of motor performance deterioration or tremor
parameters. These results imply that the development of
valproate-related motor symptoms might be inﬂuenced by
individual predisposition, but its nature is not yet identiﬁed.
The analysis of follow-up results was not the aim of the present
study. However, because one of the patients (Patient No. 12, Table
2b) had pathological values in all subtests of the quantitative
assessment, we performed a control examination 3 months later.
We noted further deterioration of motor performance, and the
patient complained of hand tremor. To avoid further decline
valproate treatment was replaced. Six months later the control
quantitative test showed signiﬁcant improvement, however the
results were still below normal.
One drawback of our study is that the scientiﬁcally most robust
protocol, i.e. the challenge–dechallenge–rechallenge design re-
garding valproate treatment could not be applied, most impor-
tantly, because of the withdrawal of the drug might lead to seizure
exacerbation. Another reason is that although valproate-induced
motor symptoms are reversible but the recovery might take
several months. Therefore, this trial design would have been
difﬁcult to implement in practice.
Since patients with epilepsy may differ from normal controls in
a number of ways, regardless of antiepileptic drug therapy, a more
valid control group might have been patients taking otherantiepileptic drugs. This approach however also seems problem-
atic since most antiepileptic drugs (phenytoin, benzodiazepines,
carbamazepine, topiramate, gabapentine, and lamotrigine) are
known to cause tremor and ataxia.24
Wedid not intend to prove that valproate inducesmotor adverse
reactions, since this is already a well-established fact.25 Instead, we
investigated epilepsy patients who were on chronic valproate
therapy and were free of motor complaints in order to demonstrate
subclinical signs of motor performance deterioration. Our results
suggest that in themajority of valproate-treated patients signiﬁcant
irregularity of alternating hand and repetitive ﬁnger movements
could be detected using quantitative methods. This phenomenon
most probably is not related to the epilepsy disorder itself, since
discontinuation of the drug leads to considerable improvement.
5. Conclusion
We propose that quantitative methods might be used for
objective evaluation andmonitoring themotor performance status
of patients on chronic valproate therapy. In case of progressive
deterioration, discontinuation of the drug might be initiated.
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